The covenant relaxation confirms severe operating stress from the lost VA CMOP contract and deteriorating financials. Monitor Q3 FY2026 results (due August 2026) for compliance with loosened covenants and any draw on the $100M shelf offering, which would signal an equity raise and further dilution. The company's ability to win large new contracts is critical to avoid a future covenant breach.
Price Chart
Executive Summary
DLH Holdings entered into a Second Amendment to its credit agreement on June 11, 2026, securing covenant relief as its financial condition deteriorates. The amendment relaxes leverage and coverage ratios, expands EBITDA add-backs for restructuring costs and lease termination, and excludes undrawn VA CMOP letters of credit from Total Funded Debt. The term loan principal was reduced to $122M through amortization, but the company faces a severe revenue decline (33.6% YoY) following the loss of its VA CMOP pharmacy contract.
Key Facts
- Term loan amortized to $122,000,000 from $142,500,000 as of the Second Amendment effective date.
- Maximum Total Leverage Ratio increased to 5.50:1.00 for the fiscal quarter ending September 30, 2026 (from 4.75:1.00 prior).
- Minimum Fixed Charge Coverage Ratio reduced to 1.05:1.00 for fiscal quarters ending June 30, 2026 and September 30, 2026 (from 1.10:1.00 prior).
- Consolidated EBITDA definition expanded to include lease termination costs, cash restructuring charges, and up to $3 million of pro forma net income from new material contract awards.
- Total Funded Debt definition amended to exclude undrawn letters of credit related to the VA's Consolidated Mail Outpatient Pharmacy (CMOP) program.
- Cross-filing context: S-3 shelf registration filed June 4, 2026 (13 days prior) for up to $100M in securities, indicating likely capital raise to address liquidity.
- Company reported Q2 FY2026 revenue of $59.3M (down 33.6% YoY) and a net loss of $2.5M with only $131K cash on hand in its most recent 10-Q.
Financial Impact
Covenant relief signals imminent default risk without amendment; $122M term loan and $50M revolver remain in place with relaxed financial tests.
Risk Factors
- Revenue decline may accelerate without replacement of lost VA CMOP revenue
- Potential equity dilution from the $100M shelf registration to address liquidity needs
- Increased leverage from already high debt load relative to declining EBITDA
- Risk of further covenant breach if new contract awards do not materialize
- Restructuring charges and lease exit costs may not sufficiently improve cash flow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-043937 |
| Document: dlhc-20260611.htm | 0001628280-26-043937 |
| Document: 0001628280-26-043937-index-headers.html | 0001628280-26-043937 |
| Document: 0001628280-26-043937-index.html | 0001628280-26-043937 |
| Document: 0001628280-26-043937.txt | 0001628280-26-043937 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | Press Release | $4.01 | awaiting T+60 | — | $3.67 (−8.36%) |
Sep 28, 2026 28d ago | Press Release | $3.46 | awaiting T+60 | — | $3.67 (+6.07%) |
Sep 14, 2026 5w ago | Press Release | $3.63 | awaiting T+60 | — | $3.67 (+1.10%) |
Jul 6, 2026 15w ago | 8-K | $5.25 $3.70 | ▼ −29.52% | ▼ −31.52% | $3.67 (−30.10%) |
Jun 17, 2026 18w ago | 8-K | $5.44 $3.76 | ▲ +30.88% | ▲ +32.78% | $3.67 (+32.54%) |
Jun 16, 2026 18w ago | EFFECT | $5.47 $4.01 | ▲ +26.69% | ▲ +27.69% | $3.67 (+32.91%) |
Jun 4, 2026 20w ago | S-3 | $5.58 $4.35 | ▲ +22.13% | ▲ +26.13% | $3.67 (+34.23%) |
May 6, 2026 24w ago | 8-K | $5.73 $5.02 | ▲ +12.39% | ▲ +16.22% | $3.67 (+35.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers